P

Parenteral Drugs (India) Ltd

PDPL NSE

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Parenteral Drugs (India) Ltd insights

29 extracted metrics + investor summaries across FY11–FY22.

Log in — free

Tapetide Score

Data-driven rating, 0–100. How it works →

Technical Indicators

Key Insights

Strengths

1
  • Company has reduced debt.

Weaknesses

4
  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of -48.3% over past five years.
  • Contingent liabilities of Rs.135 Cr.
  • Company's cost of borrowing seems high

Growth Rate

Revenue Growth
-30.00% →
Net Income Growth
-6.00% →
Cash Flow Change
-
ROE
-
ROCE
-
EBITDA Margin (Avg.)
-

Quarterly Results

  Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022
Sales
2
9
7
7
9
3
5
2
3
3
2
1
2
Expenses
12
13
11
10
13
9
11
5
-1
6
6
5
8
Operating Profit
-9
-4
-4
-3
-4
-6
-6
-3
3
-3
-3
-3
-6
OPM %
-387%
-46%
-50%
-41%
-48%
-200%
-139%
-141%
132%
-90%
-139%
-224%
-333%
Other Income
1
0
0
0
0
0
0
0
0
0
0
0
52
Interest
25
26
27
28
29
30
31
32
32
34
35
37
0
Depreciation
55
4
4
4
4
4
4
4
4
4
4
4
27
PBT
-88
-34
-35
-35
-37
-40
-42
-39
-33
-41
-43
-44
19
Tax %
-18%
-19%
-19%
-26%
-13%
-19%
-19%
-21%
-26%
-22%
-22%
-22%
-24%
Net Profit
-72
-28
-28
-26
-32
-32
-34
-31
-25
-32
-34
-35
24
EPS in Rs
-24.13
-9.29
-9.49
-8.77
-10.71
-10.81
-11.29
-10.39
-8.33
-10.75
-11.27
-11.58
7.99
Figures in ₹ Crores

Profit & Loss

  Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022
Sales
482
333
327
274
263
260
230
224
32
32
12
8
Expenses
433
319
341
349
248
296
249
225
50
47
24
24
Operating Profit
50
14
-14
-75
14
-36
-19
-1
-18
-15
-12
-15
OPM %
10%
4.2%
-4.3%
-27%
5%
-14%
-8%
-0.5%
-55%
-46%
-97%
-177%
Other Income
1
0
0
107
1
2
3
2
1
0
0
52
Interest
29
48
56
60
70
70
86
98
96
110
125
106
Depreciation
13
14
23
19
31
23
25
24
69
17
17
40
PBT
9
-49
-93
-47
-86
-127
-127
-121
-181
-142
-154
-109
Tax %
46%
10%
16%
-3%
-22%
-8%
-8%
-8%
-18%
-20%
-21%
-30%
Net Profit
5
-53
-108
-45
-68
-117
-118
-112
-148
-114
-122
-76
EPS in Rs
1.71
-20.64
-41.69
-15.15
-22.69
-39.09
-39.52
-37.5
-49.61
-38.26
-40.82
-25.61
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
Figures in ₹ Crores

Balance Sheet

  Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022
Equity Capital
26
26
26
30
30
30
30
30
30
30
30
30
Reserves
300
311
203
157
82
278
-47
-166
-477
-591
-713
-854
Borrowings
332
395
501
539
581
670
772
767
638
636
636
107
Other Liabilities
97
118
105
98
92
88
159
260
349
478
615
1,201
Total Liabilities
755
850
835
825
785
1,066
914
890
541
552
568
484
Fixed Assets
406
500
610
571
542
892
739
716
356
339
322
205
CWIP
79
116
4
1
0
0
0
0
0
0
0
0
Investments
4
0
0
0
0
0
1
0
2
2
2
2
Other Assets
267
233
221
253
242
174
175
175
182
210
244
276
Total Assets
755
850
835
825
785
1,066
914
890
541
552
568
484
Figures in ₹ Crores

Cash Flow

  Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022
Operating
78
20
-168
-60
2
58
134
167
477
112
125
0
Investing
-113
-147
-18
33
3
-110
-1
-1
97
0
0
65
Financing
31
133
182
25
-10
54
-134
-167
-574
-112
-125
-64
Net Cash Flow
-5
5
-3
-2
-5
1
0
0
0
0
0
0
Free Cash Flow
-31
-127
-188
-38
-3
-52
134
166
576
112
125
64
CFO/OP
164
143
1,193
77
12
-162
-692
-14,269
-2,700
-765
-1,065
3
Figures in ₹ Crores

Ratios

  Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022
Debtor Days
81
101
88
161
194
130
99
6
0
0
0
0
Inventory Days
118
149
121
128
232
112
107
68
224
73
103
69
Days Payable
79
157
112
99
177
77
101
130
671
458
504
654
Cash Conversion Cycle
120
93
97
189
249
164
105
-55
-446
-385
-401
-585
Working Capital Days
-19
-73
22
34
3
-198
-491
-810
-9,244
-10,747
-32,260
-48,682
ROCE %
6%
0%
-5%
-4%
-2%
-7%
-5%
-3%
-21%
-24%
-213%
—

Shareholding Pattern

As of Mar 2022
Promoters 73.29%
Public 26.71%
DIIs 0.01%
Total 100.01%
  Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022
Promoters
73.28%
73.28%
73.28%
73.28%
73.28%
73.28%
73.28%
73.28%
73.28%
73.28%
73.28%
73.29%
DIIs
0.01%
0.01%
0.03%
0.01%
0.01%
0.01%
0.01%
0.01%
0.01%
0.01%
0.01%
0.01%
Public
26.71%
26.71%
26.69%
26.71%
26.71%
26.71%
26.71%
26.71%
26.71%
26.71%
26.71%
26.71%
No. of Shareholders
7,396
7,378
7,330
7,296
7,295
7,300
7,300
7,269
7,205
7,183
7,164
7,129

Documents

Frequently Asked Questions about Parenteral Drugs (India) Ltd

What does Parenteral Drugs (India) Ltd do?
Incorporated in 1983, Parenteral Drugs Ltd is engaged in Manufacturing and Trading of Pharmaceutical Products
Where is Parenteral Drugs (India) Ltd (PDPL) listed?
Parenteral Drugs (India) Ltd is listed on the Indian stock exchanges. It is listed on NSE: PDPL and BSE: 524689. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Parenteral Drugs (India) Ltd belong to?
Parenteral Drugs (India) Ltd operates in the Healthcare sector within the Pharmaceuticals & Biotechnology industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
How can I research Parenteral Drugs (India) Ltd on Tapetide?
On Tapetide, you can view Parenteral Drugs (India) Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.

Company Information

Incorporated in 1983, Parenteral Drugs Ltd is engaged in Manufacturing and Trading of Pharmaceutical Products

Website pdindia.com
Listed 2006-03-01
Face Value ₹ 10

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List